Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Excerpt from the Press Release:

Monotherapy data further enhances confidence in CUE-101 potential as single agent therapeutic in the refractory/metastatic human papillomavirus positive head and neck squamous cell carcinoma (HPV+ HNSCC) setting

Early CUE-101 combination data with KEYTRUDA^® (pembrolizumab) supports potential mechanistic activity

CUE-102 in vivo data demonstrated ability to selectively activate and expand Wilms’ Tumor 1 (WT1)-specific T cells for the treatment of WT1-expressing cancers, supporting clinical advancement of CUE-102

CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today the presentation of interim data further demonstrating the tolerability and antitumor activity potential of CUE-101 as a monotherapy as part of the Company’s ongoing clinical trial for the treatment of recurrent/metastatic HPV+ head and neck cancer in a poster at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021). Early data from the CUE-101 combination study with pembrolizumab will also be discussed, supporting the potential for mechanistic activity in frontline HPV+ HNSCC patients. SITC 2021 will be held in Washington, D.C. and virtually November 10-14.

Click the button below to read the entire Press Release:

Continue Reading The Press Release